Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.
Back
Reviewing How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations
Saurabh Dahiya, MD, FACP, and Shyam A. Patel, MD, PhD, discuss their research into the risk of developing second primary cancers following CAR T-cell therapy and how this risk, though low, may be mitigated.
Reviewing How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations
Episodes
All
All
Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.
Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.
Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.
Drs Dahiya and Patel discuss how SPC research may help optimize CAR T-cell product development in the future.
CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5